Journal Article Gives Insight On Using Personal Preference Information In Clinical Trials
Executive Summary
The FDA has expressed interest in using patient preference information (PPI) to make regulatory decisions for medical devices. A recent article gives recommendations to medical device sponsors who want to study PPI in clinical trials.
You may also be interested in...
Preferential Treatment: US FDA Asks Patients For Their Input
As the agency continues to incorporate more patient-preference data into its regulatory process, it is asking stakeholders on the kinds of diseases and other factors it should consider when evaluating patient-preference information. The feedback is ultimately meant to inform regulators and sponsors about what patients want as they develop products.
Final Guidance Encourages Use Of Patient Preference In Device Applications
US FDA released a final guidance aimed at helping sponsors and other stakeholders interested in using patient-preference information to make their case for a device application. The agency has decided to keep its labeling recommendation in the final guidance despite industry objections.
CDS Final Guidance Draws More Criticism, This Time From Congress
Senator Bill Cassidy says FDA “disregarded” Congressional intent by expanding its authority to regulate clinical decision support software.